253 related articles for article (PubMed ID: 17982637)
1. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions.
Economidou F; Tzortzaki EG; Schiza S; Antoniou KM; Neofytou E; Zervou M; Lambiri I; Siafakas NM
Oncol Rep; 2007 Dec; 18(6):1507-12. PubMed ID: 17982637
[TBL] [Abstract][Full Text] [Related]
2. p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion.
Lee JH; Hong YS; Ryu JS; Chang JH
Lung Cancer; 2004 Apr; 44(1):33-42. PubMed ID: 15013581
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite alterations and cell-free DNA analysis: could they increase the cytology sensitivity in the diagnosis of malignant pleural effusion?
Carpagnano GE; Costantino E; Palladino GP; Lacedonia D; Martinelli D; Orlando S; Foschino-Barbaro MP
Rejuvenation Res; 2012 Jun; 15(3):265-73. PubMed ID: 22551519
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology.
Woenckhaus M; Grepmeier U; Werner B; Schulz C; Rockmann F; Wild PJ; Röckelein G; Blaszyk H; Schuierer M; Hofstaedter F; Hartmann A; Dietmaier W
J Mol Diagn; 2005 Oct; 7(4):517-24. PubMed ID: 16237222
[TBL] [Abstract][Full Text] [Related]
5. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
6. Potential use of loss of heterozygosity in pleural effusions of breast cancer metastases using the microsatellite marker of the 16q22.1 region of the CDH1 gene.
Granja Nde M; Ricardo SA; Longatto Filho A; Alves VA; Bedrossian CW; Wiley EL; Schmitt FC
Anal Quant Cytol Histol; 2005 Apr; 27(2):61-6. PubMed ID: 15913197
[TBL] [Abstract][Full Text] [Related]
7. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
[TBL] [Abstract][Full Text] [Related]
9. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
Lung; 2017 Oct; 195(5):653-660. PubMed ID: 28656381
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions.
Han J; Cao S; Zhang K; Zhao G; Xin Y; Dong Q; Yan Y; Cui J
J Cardiothorac Surg; 2012 Nov; 7():121. PubMed ID: 23148562
[TBL] [Abstract][Full Text] [Related]
11. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
Brock MV; Hooker CM; Yung R; Guo M; Han Y; Ames SE; Chang D; Yang SC; Mason D; Sussman M; Baylin SB; Herman JG
Ann Thorac Surg; 2005 Oct; 80(4):1241-7. PubMed ID: 16181847
[TBL] [Abstract][Full Text] [Related]
12. No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancer.
Pylkkänen L; Karjalainen A; Anttila S; Vainio H; Husgafvel-Pursiainen K
Environ Mol Mutagen; 1997; 30(2):217-23. PubMed ID: 9329646
[TBL] [Abstract][Full Text] [Related]
13. Comparison of nucleolar organiser regions and DNA flow cytometry in the evaluation of pleural effusion.
Huang MS; Tsai MS; Hwang JJ; Wang TH
Thorax; 1994 Nov; 49(11):1152-6. PubMed ID: 7831633
[TBL] [Abstract][Full Text] [Related]
14. Analysis of pleural effusions using flow cytometry.
Ceyhan BB; Demiralp E; Celikel T
Respiration; 1996; 63(1):17-24. PubMed ID: 8833988
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
16. Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
Tiran V; Stanzer S; Heitzer E; Meilinger M; Rossmann C; Lax S; Tsybrovskyy O; Dandachi N; Balic M
PLoS One; 2017; 12(4):e0175223. PubMed ID: 28423035
[TBL] [Abstract][Full Text] [Related]
17. Different expression of FoxM1 in human benign and malignant pleural effusion.
Tang Z; Li H; Zhu H; Bai C
Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
[TBL] [Abstract][Full Text] [Related]
18. Routine DNA cytometry of benign and malignant pleural effusions by means of the remote quantitation server Euroquant: a prospective study.
Kayser K; Blum S; Beyer M; Haroske G; Kunze KD; Meyer W
J Clin Pathol; 2000 Oct; 53(10):760-4. PubMed ID: 11064669
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of breast cancer metastases in pleural effusions by molecular biology techniques.
de Matos Granja N; Soares R; Rocha S; Paredes J; Longatto Filho A; Alves VA; Wiley E; Schmitt FC; Bedrossian C
Diagn Cytopathol; 2002 Oct; 27(4):210-3. PubMed ID: 12357497
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite alterations and loss of heterozygosity in Peyronie's disease.
Perinchery G; El-Sakka AI; Angan A; Nakajima K; Dharia A; Tanaka Y; Lue TF; Dahiya R
J Urol; 2000 Sep; 164(3 Pt 1):842-6. PubMed ID: 10953165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
